Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
about
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?Mogamulizumab for the treatment of T-cell lymphoma.Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma.Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules.Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin.Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?[Treatment of mycosis fungoides and Sézary syndrome].[Treatment of rare cutaneous T‑cell lymphoma and blastic plasmacytoid dendritic cell neoplasm].Brentuximab vedotin: targeting CD30 as standard in CTCL.Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.Current Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasManagement of Lymphomas: Consensus Document 2018 by an Indian Expert Group
P2860
Q38643068-8FD841A4-A187-4B5B-82BB-063B573A399DQ39432325-89FE4FB6-A857-4E63-BB52-F699EBA854AAQ47102763-66922250-94B6-4F34-B7FD-632E998F2A2DQ47851750-7C2B4372-E0BC-4ABB-9656-74B5867358C4Q48098307-CC5325CB-50DC-4E7F-8A4B-76CB46EA80DDQ48202619-43E30205-BD30-4CEA-9130-AD8A9E4CE5A8Q48223870-2E11084E-3241-4C3D-A8D3-8986A446D8B3Q48248214-178DFBF0-BF38-47F3-88F6-A05A9C901AB4Q48274115-A0950164-1988-45FF-9B71-8F57EB5AD246Q49887083-28535FBD-522A-4171-83C8-AAF15B942400Q50092158-752367F6-6578-4C83-8283-49C9ED7D11D8Q50125442-502D0227-D05F-49F8-BD63-2A798368CB53Q53128681-F29D4D64-CE3F-4D90-87C5-F41FC115CAEDQ54437121-751AA7F8-3515-4B07-B738-20F6FBDBA394Q54940677-E97CB26B-9181-49AD-893F-60118BB1E5F8Q54964939-FE5E3F20-9277-43F9-8A6B-3A3973CB97D4Q55094448-B3C472A4-0150-4EAB-9799-4D653BC25670Q55334211-3821142A-4D28-43B8-BA25-1D7FC4C59CE4Q55341751-0593B753-45E0-4A43-BF23-25788F1008A4Q58723337-1A7D0871-39AD-436B-9294-003939761DD4Q58801965-2B5E0088-8B85-4761-BD3E-1B8FF092D7C3
P2860
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@en
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@nl
type
label
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@en
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@nl
prefLabel
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@en
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@nl
P2093
P50
P1433
P1476
Brentuximab vedotin or physici ...... d, phase 3, multicentre trial.
@en
P2093
ALCANZA study group
David Fisher
Dirk Huebner
Erin Zagadailov
H Miles Prince
Hui-Min Lin
Jose A Sanches
Judith Trotman
Julia Scarisbrick
Kerry Taylor
P304
P356
10.1016/S0140-6736(17)31266-7
P407
P577
2017-06-06T00:00:00Z